Goldman Sachs’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-518
| Closed | -$5K | – | 5307 |
|
|
2024
Q4 | $5K | Sell |
518
-3,539
| -87% | -$34.2K | ﹤0.01% | 4963 |
|
|
2024
Q3 | $75.4K | Sell |
4,057
-8,464
| -68% | -$157K | ﹤0.01% | 4632 |
|
|
2024
Q2 | $208K | Buy |
12,521
+5,543
| +79% | +$92.2K | ﹤0.01% | 4348 |
|
|
2024
Q1 | $121K | Sell |
6,978
-13,286
| -66% | -$231K | ﹤0.01% | 4426 |
|
|
2023
Q4 | $317K | Buy |
20,264
+6,910
| +52% | +$108K | ﹤0.01% | 4154 |
|
|
2023
Q3 | $660K | Sell |
13,354
-678
| -5% | -$33.5K | ﹤0.01% | 3753 |
|
|
2023
Q2 | $1.1M | Buy |
14,032
+7,009
| +100% | +$548K | ﹤0.01% | 3563 |
|
|
2023
Q1 | $636K | Sell |
7,023
-2,374
| -25% | -$215K | ﹤0.01% | 3948 |
|
|
2022
Q4 | $1.11M | Buy |
9,397
+1,861
| +25% | +$220K | ﹤0.01% | 3639 |
|
|
2022
Q3 | $1.37M | Sell |
7,536
-2,406
| -24% | -$436K | ﹤0.01% | 3643 |
|
|
2022
Q2 | $892K | Buy |
9,942
+5,242
| +112% | +$470K | ﹤0.01% | 4027 |
|
|
2022
Q1 | $730K | Buy |
4,700
+674
| +17% | +$105K | ﹤0.01% | 4338 |
|
|
2021
Q4 | $1.2M | Sell |
4,026
-480
| -11% | -$143K | ﹤0.01% | 3884 |
|
|
2021
Q3 | $2.6M | Buy |
4,506
+1,078
| +31% | +$621K | ﹤0.01% | 3272 |
|
|
2021
Q2 | $1.56M | Sell |
3,428
-8,759
| -72% | -$3.98M | ﹤0.01% | 3699 |
|
|
2021
Q1 | $6.56M | Buy |
12,187
+10,871
| +826% | +$5.85M | ﹤0.01% | 2477 |
|
|
2020
Q4 | $1.16M | Sell |
1,316
-1,397
| -51% | -$1.24M | ﹤0.01% | 3367 |
|
|
2020
Q3 | $1.72M | Buy |
+2,713
| New | +$1.72M | ﹤0.01% | 2990 |
|